Story perspectives

AbbVie’s $20B Deal Talks Boost Stocks, Then Plunge

1/8/2026

Summary

Story summary

AbbVie is in negotiations to acquire Revolution Medicines, a biotech, to bolster its oncology portfolio as Humira faces patent competition.
The deal could exceed $20 billion, making it one of the largest biotech transactions in recent years.
Following the news, Revolution Medicines' shares surged nearly 30% and AbbVie's stock rose over 5%.
AbbVie later denied being in talks, causing Revolution Medicines' shares to fall 11.5%, and the outcome remains uncertain.

History

Historical Context

In December 2000, Glaxo Wellcome and SmithKline Beecham merged to create GlaxoSmithKline (GSK), valued at £114 billion, marking a significant consolidation in the pharmaceutical industry. This trend continued as companies sought to enhance their portfolios amid patent expirations. Recently, AbbVie’s negotiations to acquire Revolution Medicines for over $20 billion reflect ongoing efforts to strengthen oncology offerings in a competitive market.

1 of 2

Story summary

AbbVie is in negotiations to acquire Revolution Medicines, a biotech, to bolster its oncology portfolio as Humira faces patent competition.
The deal could exceed $20 billion, making it one of the largest biotech transactions in recent years.
Following the news, Revolution Medicines' shares surged nearly 30% and AbbVie's stock rose over 5%.
AbbVie later denied being in talks, causing Revolution Medicines' shares to fall 11.5%, and the outcome remains uncertain.

1 / 2